Oramed Pharmaceuticals Inc (ORMP)

[midastouch017]

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

https://finance.yahoo.com/news/orameds-diabetes-market-survey-shows-122500288.html

- 76 Percent of the Physicians Responded They "Definitely Would" or "Probably Would" Prescribe Oramed's Oral Insulin Candidate for Type 2 Diabetes Patients

NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey commissioned by Oramed from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

The survey included 88 Endocrinologists and 82 Primary Care Physicians in the U.S. and Europe. After reviewing the blinded target product profile for Oramed's oral insulin candidate, 76 percent of the physicians responded that they "definitely would" or "probably would" prescribe it for Type 2 diabetes patients, with only 2 percent responding that they "probably would not" or "definitely would not prescribe it". Overall, health care providers were receptive to prescribing oral insulin, if approved, and the sentiment for ORMD-0801 was very positive. Some potential benefits expressed by the physicians include less possibility of hypoglycemia or weight gain and the benefit of not using needles. Additional results and information concerning the survey can be found within the company's corporate presentation at www.oramed.com.

Oramed's Chief Executive Officer, Nadav Kidron, commented, "As we continue moving forward with our Phase 3 trials and further develop our commercialization plan, this latest survey further confirms that physicians believe our oral insulin candidate can potentially address important unmet needs for patients with Type 2 diabetes. We are excited as this could be the world's first oral insulin capsule using our proprietary platform oral delivery technology."